AxoSim's Nerve-on-a-Chip® platform is revolutionizing the way that pharmaceutical companies develop neurological drugs. Our mission is to enable advancements in human health, so that patients in need can get the care they deserve.
We deliver human data, faster. This reduces clinical failure and enables companies to develop effective drugs more quickly and at lower cost. We will become an integral part of the drug development pipeline, fostering innovation and prompting breakthroughs in the treatment of the world's most devastating diseases.
AxoSim was founded to address unsustainably high clinical failure rates that cost pharmaceutical companies billions of dollars and patients years of waiting for medications and therapies. An astounding 89% of all new drugs, and 94% of neurological drugs, fail in clinical trials. The reason: animal testing cannot predict human results. To us, that was unacceptable: researchers, pharmaceutical companies, and patients in need deserve better.
So, in 2014, AxoSim spun out of Tulane University to solve the challenge of modeling human results in vitro. Our Nerve-on-a-Chip® platform predicts clinical performance in the lab, helping pharmaceutical partners develop safer and more effective cures, and save millions of dollars and years of development time in the process. We are working to rapidly expand the applications of our platform to address the growing burden of neurodegenerative diseases.
AxoSim has grown out of its humble beginnings at Tulane University to become a powerhouse of innovation in the pharmaceutical industry and in the startup scene here in New Orleans.
Today, our offices are located in the New Orleans BioInnovation Center, the city's first LEED Gold-certified laboratory building. This cutting-edge facility in the heart of downtown positions our company to continue to be at the forefront of emerging technology and research. We have the facilities and the team we need to accomplish our goals and have a fundamental impact on the way all neurological drugs are developed.
We believe that we can truly make a difference in the development of drugs to combat MS, ALS, Alzheimer’s, and Parkinson’s. That is why our team is made up of driven, creative individuals, all of whom are passionate about disrupting – and accelerating – the preclinical testing process.